OlympiAD: Further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician’s choice
Year: 2017
Type: article
Source: Annals of Oncology
Institutions: Institut Gustave Roussy, University of Padua, Istituto Oncologico Veneto, Seoul National University, Seoul National University Hospital, Gdańsk Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College, University of Pennsylvania, Osaka National Hospital, First Hospital of Jilin University, Beth Israel Deaconess Medical Center, Harvard University, Dana-Farber/Harvard Cancer Center, University of Manchester, The Christie Hospital, The Christie NHS Foundation Trust, AstraZeneca (United States), AstraZeneca (United Kingdom), Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2761005087